about
Expression of neurexin, neuroligin, and their cytoplasmic binding partners in the pancreatic beta-cells and the involvement of neuroligin in insulin secretionNeurexin-1α contributes to insulin-containing secretory granule dockingDrug-induced liver injury: Advances in mechanistic understanding that will inform risk management.A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis.Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred micePPARγ coactivator-1α contributes to exercise-induced regulation of intramuscular lipid droplet programming in mice and humans.Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury?Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials.Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance.Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug.miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.Optimized Methods to Explore the Mechanistic and Biomarker Potential of Hepatocyte-Derived Exosomes in Drug-Induced Liver Injury.Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa).Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.Challenges and Solutions for Future Pharmacy Practice in the Era of Precision MedicineMouse Population-Based Approaches to Investigate Adverse Drug ReactionsQuantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-induced Liver InjuryMechanisms of Drug-induced Liver InjuryBioprinted liver provides early insight into the role of Kupffer cells in TGF-β1 and methotrexate-induced fibrogenesisUnderstanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver InjuryIdentification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross ApproachHepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury
P50
Q28572953-050B0E36-B5F8-4FAB-A7FC-3AA5390BCA93Q28578639-A767FED0-D675-4106-8F45-C5A95EBDA2BFQ30241050-3CB1A22D-498C-49AA-9141-7A5B3F26A0DBQ34208933-E1B691C3-12B2-46AC-AF3F-FDE7870C542FQ35071460-D66051E1-05BC-43B5-BD64-E385FBD45645Q36658412-865FBD91-60A0-46D5-AF69-BA60CC6F8D41Q36935435-FC6D21DA-EE30-4A84-9AB4-495E6C65D723Q37564187-59C715A8-7D2E-4D39-952C-05754750864AQ38374943-63CBF6DA-22F0-43D6-933F-67D16025A07CQ40028148-9452DF14-BD5C-4CBA-9028-F8EEAB020A84Q46874116-5B3549C8-2C14-4171-A74A-B152A0202217Q47446885-C66A8922-824A-4323-B1BB-0DD5E011AE89Q47701849-0AA433E2-8C2C-49F5-993C-B75A4E193853Q47719721-2B5A301B-440D-42ED-9FD0-4A08B680D7DAQ51172729-FE95824C-D582-46A8-B74D-69D7832E8431Q57171377-0E17A6AE-0085-4A69-A1ED-607BA827ED08Q59515987-C6DFE76A-4792-494A-B750-558FBC9110B0Q59515990-22D6EFB5-EF4C-4A46-A15A-DFD1728313FEQ59515992-AD5428BB-C6C2-483E-88D8-3912C3EAA310Q60922352-B656100D-AF42-4422-89BE-C380946711C7Q89618251-D1A15D19-0D4D-4014-A490-B0EB338F33E6Q90006694-97827F21-27E3-4925-9E80-85753D424203Q92058743-0794E662-6DC4-4346-A4F3-533F100BB399
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Merrie Mosedale
@ast
Merrie Mosedale
@en
Merrie Mosedale
@es
Merrie Mosedale
@nl
Merrie Mosedale
@sl
type
label
Merrie Mosedale
@ast
Merrie Mosedale
@en
Merrie Mosedale
@es
Merrie Mosedale
@nl
Merrie Mosedale
@sl
prefLabel
Merrie Mosedale
@ast
Merrie Mosedale
@en
Merrie Mosedale
@es
Merrie Mosedale
@nl
Merrie Mosedale
@sl
P106
P21
P31
P496
0000-0003-1968-6666
P569
2000-01-01T00:00:00Z